Provided by Tiger Trade Technology Pte. Ltd.

Ligand Pharmaceuticals

280.18
-6.1100-2.13%
Post-market: 280.180.00000.00%19:30 EDT
Volume:158.24K
Turnover:44.66M
Market Cap:5.59B
PE:28.85
High:286.27
Open:286.27
Low:279.87
Close:286.29
52wk High:326.63
52wk Low:157.52
Shares:19.94M
Float Shares:19.35M
Volume Ratio:0.86
T/O Rate:0.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):9.71
EPS(LYR):6.13
ROE:21.96%
ROA:3.99%
PB:5.77
PE(LYR):45.71

Loading ...

Dec 01, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Nov 08, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Nov 07, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Nov 07, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 06, 2025

Major Issues Report

Form 8-K - Current report
Nov 04, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Oct 01, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Sep 23, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Sep 17, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Sep 16, 2025

Major Issues Report

Form 8-K - Current report
Sep 02, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 15, 2025

Major Issues Report

Form 8-K - Current report
Aug 11, 2025

Major Issues Report

Form 8-K - Current report
Aug 08, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 07, 2025

Major Issues Report

Form 8-K - Current report
Aug 01, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jul 10, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jul 02, 2025

Major Issues Report

Form 8-K - Current report
Jun 23, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 10, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities